Investor Ideas Biotech and Pharma Stocks News Alert: BioSante Pharmaceuticals Added to NASDAQ Biotechnology Index

LINCOLNSHIRE, Ill. - November 21, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc.

, today announced that it has been added to the NASDAQ Biotechnology Index:

, effective prior to the stock market open today, November 21, 2011. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (

). The NASDAQ Biotechnology Index is a modified market capitalization-weighted index, and the index securities are evaluated semi-annually in May and November. "We are delighted that BioSante has been added to the NASDAQ Biotechnology Index, as it recognizes our established role in the biotechnology industry, adds greater visibility for our company and could lead to a broader stockholder base," stated Phillip Donenberg, BioSante's senior vice president of finance and chief financial officer. About BioSante Pharmaceuticals, Inc. BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (

), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (

). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development. Additional information is available online at: www.biosantepharma.com. Contact: For Investors: The Trout Group LLC Tricia Swanson (646) 378-2953 tswanson@troutgroup.com or For Media: Harris D. McKinney, Inc. Alan Zachary 312-506-5220 azachary@harrisdmckinney.com BioSante Pharmaceuticals, Inc:

is a featured showcase biotech/pharma stock on Investorideas.com Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp About InvestorIdeas.com: InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks. Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp Source: Investorideas.com, BioSante, Investorideas.com 800 665 0411 cvanzant@investorideas.com